GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shenzhen Bioeasy Biotechnology Co Ltd (SZSE:300942) » Definitions » EBIT

Shenzhen Bioeasy Biotechnology Co (SZSE:300942) EBIT : ¥-58.6 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shenzhen Bioeasy Biotechnology Co EBIT?

Shenzhen Bioeasy Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥9.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-58.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shenzhen Bioeasy Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 was 5.83%. Shenzhen Bioeasy Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 7.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shenzhen Bioeasy Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -1.81%.


Shenzhen Bioeasy Biotechnology Co EBIT Historical Data

The historical data trend for Shenzhen Bioeasy Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Bioeasy Biotechnology Co EBIT Chart

Shenzhen Bioeasy Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 97.91 74.31 270.42 98.97 -167.17

Shenzhen Bioeasy Biotechnology Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.28 -75.43 -1.94 8.97 9.76

Competitive Comparison of Shenzhen Bioeasy Biotechnology Co's EBIT

For the Biotechnology subindustry, Shenzhen Bioeasy Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Bioeasy Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shenzhen Bioeasy Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shenzhen Bioeasy Biotechnology Co's EV-to-EBIT falls into.


;
;

Shenzhen Bioeasy Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-58.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Bioeasy Biotechnology Co  (SZSE:300942) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shenzhen Bioeasy Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=48.896 * ( 1 - 17.07% )/( (678.668 + 712.679)/ 2 )
=40.5494528/695.6735
=5.83 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1394.155 - 98.548 - ( 623.912 - max(0, 158.535 - 775.474+623.912))
=678.668

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1378.757 - 84.055 - ( 582.023 - max(0, 141.702 - 733.305+582.023))
=712.679

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shenzhen Bioeasy Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=39.04/( ( (466.476 + max(19.496, 0)) + (498.796 + max(37.013, 0)) )/ 2 )
=39.04/( ( 485.972 + 535.809 )/ 2 )
=39.04/510.8905
=7.64 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(77.568 + 41.045 + 19.71) - (98.548 + 0 + 20.279)
=19.496

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(83.046 + 38.721 + 19.276) - (84.055 + 0 + 19.975)
=37.013

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shenzhen Bioeasy Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-58.631/3235.610
=-1.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Bioeasy Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Shenzhen Bioeasy Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Bioeasy Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
Liuxian 1st Road, Xin'an Street, 101, Yirui Biological Building, Xingdong Community, Bao'an District, Guangdong Province, Shenzhen, CHN, 518101
Shenzhen Bioeasy Biotechnology Co Ltd is dedicated towards food and drug safety, clinical diagnosis, public safety and other fields. It produces and sells clinical diagnosis products. It develops testing products for nine areas closely related to people's lives which include food safety, agricultural product safety, dairy product safety, meat safety, aquatic product safety, honey safety, clinical diagnosis, drug safety, and public safety.
Executives
Fu Hui Directors, executives

Shenzhen Bioeasy Biotechnology Co Headlines

No Headlines